Michael Cookson to Antineoplastic Agents
This is a "connection" page, showing publications Michael Cookson has written about Antineoplastic Agents.
Connection Strength
1.429
-
Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17; 355:i4405.
Score: 0.356
-
Trends in the use of perioperative chemotherapy for localized and locally advanced muscle-invasive bladder cancer: a sign of changing tides. Eur Urol. 2015 Jan; 67(1):165-170.
Score: 0.295
-
Castration-resistant prostate cancer: AUA Guideline. J Urol. 2013 Aug; 190(2):429-38.
Score: 0.280
-
Antiadenovirus Antibodies Predict Response Durability to Nadofaragene Firadenovec Therapy in BCG-unresponsive Non-muscle-invasive Bladder Cancer: Secondary Analysis of a Phase 3 Clinical Trial. Eur Urol. 2022 03; 81(3):223-228.
Score: 0.127
-
The changing landscape in the management of newly diagnosed castration sensitive metastatic prostate cancer. Investig Clin Urol. 2020 02; 61(Suppl 1):S3-S7.
Score: 0.111
-
Recent trends in the management of advanced prostate cancer. F1000Res. 2018; 7.
Score: 0.102
-
Concomitant CIS on TURBT does not impact oncological outcomes in patients treated with neoadjuvant or induction chemotherapy followed by radical cystectomy. World J Urol. 2019 Jan; 37(1):165-172.
Score: 0.100
-
Adjuvant weekly docetaxel for patients with high risk prostate cancer after radical prostatectomy: a multi-institutional pilot study. J Urol. 2007 May; 177(5):1777-81.
Score: 0.046
-
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol. 2007 Jun; 177(6):2106-31.
Score: 0.012